Citations

Showing 10 of 108094 citations.

Faculty Opinions recommendation of The Effect of Adding Subarachnoid Epinephrine to Hyperbaric Bupivacaine and Morphine for Repeat Cesarean Delivery: A Double-Blind Prospective Randomized Control Trial.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732041003.793544337 Get It

Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET
Stonnington, Cynthia M. , Chen, Yinghua , Savage, Cary R. , Lee, Wendy , Bauer, Robert, Sharieff, Sameen, Alexander, Gene E. , Caselli, Richard J. , Reiman, Eric M. , Locke, Dona E.C. , Thiyyagura, Pradeep , Chen, Kewei

Mayo Clinic

Journal of Alzheimer’s Disease | April 6, 2018 | Volume: 63 | Issue: 2 | Pages: 603-615

10.3233/jad-170852 | PMID 29630550 Get It

Background: Brain imaging measurements can provide evidence of possible preclinical Alzheimer’s disease (AD). Their ability to predict individual imminent clinical conversion remains unclear. Objective: To investigate the ability of pre-specified volumetric magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) measurements to predict which cognitively unimpaired older participants would subsequently progress to amnestic mild cognitive impairment (aMCI) within 2 years. Methods: From an apolipoprotein E4 (APOE4) enriched prospective cohort study, 18 participants subsequently progressed to the clinical diagnosis of aMCI or probable AD dementia within 1.8±0.8 years (progressors); 20 participants matched for sex, age, education, and APOE allele dose remained cognitively unimpaired for at least 4 years (nonprogressors). A complementary control group not matched for APOE allele dose included 35 nonprogressors. Groups were compared on baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD and by voxel-wise differences in regional gray matter volume and glucose metabolism. Receiver Operating Characteristic, binary logistic regression, and leave-one-out procedures were used to predict clinical outcome for the a priori measures. Results: Compared to non-progressors and regardless of APOE-matching, progressors had significantly reduced baseline MRI and PET measurements in brain regions preferentially affected by AD and reduced hippocampal volume was the strongest predictor of an individual’s imminent progression to clinically significant memory decline (79% sensitivity/78% specificity among APOE-matched cohorts). Conclusion: Regional MRI and FDG-PET measurements may be useful in predicting imminent progression to clinically significant memory decline.
Neuroregeneration: Spatial Differences in Cellular and Molecular Responses as a Function of the Material Used in Conduit‐Mediated Repair and Autograft Treatment of Peripheral Nerve Injuries (Adv. Funct. Mater. 12/2018)
Daly, William T. , Niemier, Ryan, Dillon, Simon T. , Mirsky, Rhona, Jessen, Kristján R. , Windebank, Anthony J. , Wang, Huan , Pandit, Abhay

Mayo Clinic

Advanced Functional Materials | April 6, 2018 | Volume: 28 | Issue: 12 | Pages: No page available

10.1002/adfm.201870080 Get It

Surgical Management of Abduction Deficits
B.M., Jonathan M. Holmes

Mayo Clinic

American Orthoptic Journal | April 6, 2018 | Volume: 50 | Issue: 1 | Pages: 36-41

10.1080/0065955x.2000.11982232 Get It

Head Tilt Due to Null-Point See-Saw Nystagmus
Armitage, M. Diane, Rosen, Carl E., Younge, Brian R., Arnold, Robert W.

Mayo Clinic

American Orthoptic Journal | April 6, 2018 | Volume: 46 | Issue: 1 | Pages: 181-184

10.1080/0065955x.1996.11982091 Get It

Remarks on Fixation Disparity
Martens, Theodore G.

Mayo Clinic

American Orthoptic Journal | April 6, 2018 | Volume: 20 | Issue: 1 | Pages: 68-74

10.1080/0065955x.1970.11982264 Get It

Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy
Wang, Rong , Zhou, Tingyang, Zuo, Li , Liu, Wei

Mayo Clinic

Oncotarget | April 6, 2018 | Volume: 9 | Issue: 26 | Pages: 18637-18647

10.18632/oncotarget.24746 | PMID 29719632 Get It

Safety in Acute Pain Medicine—Pharmacologic Considerations and the Impact of Systems-Based Gaps
Taenzer, Andreas H. , Elkassabany, Nabil , Wendling, Linda Le, Nin, Olga C. , Kent, Michael L., Weingarten, Toby N. , Kent, Michael

Mayo Clinic

Pain Medicine | April 6, 2018 | Volume: 19 | Issue: 11 | Pages: 2296-2315

10.1093/pm/pny079 | PMID 29727003 Get It

When to Avoid Giving Advice on the Ethical Conduct of Research
Sharp, Richard R. , Allyse, Megan , Allyse, Megan A., Sharp, Richard R , Allyse, Megan A

Mayo Clinic

The American Journal of Bioethics | April 6, 2018 | Volume: 18 | Issue: 4 | Pages: 94-95

10.1080/15265161.2018.1431721 | PMID 29621454 Get It

Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography
Mielke, Michelle M. , Hagen, Clinton E., Xu, Jing , Chai, Xiyun, Vemuri, Prashanthi , Lowe, Val J. , Airey, David , Roberts, Rosebud O., Jack, Clifford R. , Petersen, Ronald C. , Dage, Jeffrey L. , Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Knopman, David S. , Machulda, Mary M. , Dage, Jeffrey L

Mayo Clinic

Alzheimer's & Dementia | April 5, 2018 | Volume: 14 | Issue: 8 | Pages: 989-997

10.1016/j.jalz.2018.02.013 | PMID 29626426 Get It

AbstractIntroductionWe examined and compared plasma phospho‐tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ.MethodsParticipants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181.ResultsPlasma total tau and pTau181 levels were higher in AD dementia patients than those in cognitively unimpaired. Plasma pTau181 was more strongly associated with both Aβ and tau PET. Plasma pTau181 was a more sensitive and specific predictor of elevated brain Aβ than total tau and was as good as, or better than, the combination of age and apolipoprotein E (APOE).DiscussionPlasma pTau181 may have utility as a biomarker of AD pathophysiology and as a noninvasive screener for elevated brain Aβ.